Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung
Cancer (NSCLC): Expert Perspectives on the Evolving Role of Immunotherapy

A continuing medical education activity provided by NAMCP and AAMCN

Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Perspectives on the Evolving Role of Immunotherapy is a two-part webinar series

This is Part 1 of the series focusing on management of Non-Small Cell Lung Cancer

This activity is an archive from the webinar held June 16, 2021

This activity is valid from August 1, 2021 – August 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 155,870 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Fortunately for patients with metastatic NSCLC, immune checkpoint inhibitors have become available in recent years, with more coming soon, that have showed improved efficacy, safety and outcomes, especially in patients with high levels of PD-L1 expression.

As more immunotherapies are becoming available, the treatment paradigm has grown expansive, making it difficult for clinicians and managed care professionals to make the appropriate decisions based on recent clinical data and guidelines. In this program on NSCLC, medical directors, oncologists, and nurses will learn about the optimal use of current and emerging immunotherapy treatment options and new options that are just becoming available, ultimately helping patients achieve a greater quality of life and improved clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Analyze the rationale underlying the use of immune checkpoint inhibition-based strategies for the management of advanced NSCLC

  • Evaluate key clinical data on the use of current and emerging checkpoint inhibitors in the first-line treatment of squamous or nonsquamous advanced NSCLC

  • Compare and contrast safety and efficacy profiles of current and emerging immunotherapies, both alone and in combination, in the management of advanced NSCLC

  • Evaluate novel IO-associated progression patterns and strategies for their appropriate monitoring and treatment

  • Assess strategies for anticipating, recognizing, and managing immune-related adverse events of immune checkpoint inhibitors in advanced NSCLC

     

Faculty: Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute

Disclosure:

Dr. Socinski has received research/grant support from AstraZeneca, Genentech, Novartis, Spectrum, Mirati, Cullinan, Daiichi-Sankyo, and Beigene. He serves on the speaker’s bureau for AstraZeneca, Genentech, Novartis, and Guardant.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue